BC Innovations | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BC Extra | Oct 7, 2019
Clinical News

Latest aldafermin data in NASH weigh on NGM shares

NGM shed $2.77 (20%) to $10.78 on Monday as investors appeared underwhelmed by Phase II data for aldafermin in NASH. Interim 24-week data from cohort 4 of an adaptive Phase II trial showed that treatment...
BC Week In Review | Apr 28, 2017
Clinical News

BMS-986036: Additional Ph II data

Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 for 16 weeks...
Items per page:
1 - 3 of 3